Neos Therapeutics was Downgraded to a Hold Rating at UBSBy Ryan Adsit
According to TipRanks.com, Goodman is a 1-star analyst with an average return of -0.7% and a 48.7% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Sucampo Pharmaceuticals, Jazz Pharmaceuticals, and Endo International.
Neos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.
The company has a one year high of $11.50 and a one year low of $4.85. Currently, Neos Therapeutics has an average volume of 312.5K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEOS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neos Therapeutics, Inc. operates as a pharmaceutical company, which engages in developing, manufacturing, and commercializing products using proprietary, extended-release drug delivery technology platform. It uses this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX.